SCHEMBL13740955

SCHEMBL13740955

COc1ccc2c(-c3ccncc3)c(-c3ccc(F)cc3)[nH]c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 1.00
MAPK13 O15264 8/20 1.00
MAPK12 P53778 8/20 1.00
MAPK11 Q15759 8/20 1.00
CYP19A1 P11511 2/20 0.57
GCGR P47871 2/20 0.56
ALOX5 P09917 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11781720 0.79 MAPK13 (0.66) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6646025 0.78 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11
SCHEMBL6646016 0.78 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11
SCHEMBL15073410 0.77 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11
SCHEMBL8805646 0.75 MAPK14 (0.60) MAPK14MAPK13MAPK12MAPK11CYP19A1
SCHEMBL6643643 0.74 MAPK14 (1.00) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL5031028 0.73 TUBB1 (0.78) MAPK14MAPK13MAPK12MAPK11
SCHEMBL14270472 0.72 MAPK14 (0.67) MAPK14MAPK13MAPK12MAPK11
SCHEMBL2648503 0.72 MAPK11 (1.00) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL19952909 0.71 MAPK13 (0.78) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2707369-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE Eip Pharma, LLC (US) 2014-03-19 EP claimed
WO-2012154814-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA, LLC (US) 2012-11-15 WO claimed
EP-3081568-B1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA LLC (US) 2019-11-13 EP disclosed
EP-3081568-B1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA LLC (US) 2019-11-13 EP disclosed
EP-3081568-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE Eip Pharma, LLC (US) 2016-10-19 EP disclosed
EP-3081568-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE Eip Pharma, LLC (US) 2016-10-19 EP disclosed
US-9427438-B2 Compositions and methods for treating Alzheimer's disease EIP PHARMA, LLC (US) 2016-08-30 US disclosed
EP-2707369-B1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA LLC (US) 2016-07-27 EP disclosed
EP-2707369-B1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA LLC (US) 2016-07-27 EP disclosed
US-20160030431-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA, LLC 2016-02-04 US disclosed
US-20140357638-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA, LLC (US) 2014-12-04 US disclosed
WO-2012154814-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA, LLC (US) 2012-11-15 WO disclosed
US-20120289511-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE EIP PHARMA, LLC (US) 2012-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140357638-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE APP, PSEN1, PSEN2 MAPK14 4676/4885MAPK13 4673/4885MAPK12 4165/4885
US-20120289511-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE APP, PSEN1, PSEN2 MAPK14 4676/4885MAPK13 4673/4885MAPK12 4165/4885
US-20160030431-A1 COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE APP, PSEN1, PSEN2 MAPK14 4676/4885MAPK13 4673/4885MAPK12 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.